News by Subject Policy & Ethics

Results of a new behavioral study into what influences the decision to recall a defective product found that medical device firm managers may rely on their physician-customers to screen out detectable defects, in lieu of issuing a recall.

A drug policy researcher is proposing a suite of changes to overhaul the Multi-Criteria Drug Harm Scale, which informs drug policies across Europe. The changes focus on addressing use and abuse separately, collecting input from a broader range of stakeholders, and targeting substance-specific experts for drug review panels.

Advanced directives for dementia, differentiating obese children from abused children, and more in the (July-August 2018 issue.

Americans' views of possible uses of genetic engineering in animals vary depending on the mechanism and intended purpose of the technology, particularly the extent to which it would bring health benefits to humans.

New Hastings Center special report outlines ethics and policy recommendations on genome-wide sequencing of newborns.

A powerful psychedelic compound found in ayahuasca can model near-death experiences in the brain, a study has found.

Doctors confronted with information about patient deaths by opioid overdose became more careful in prescribing the painkillers once they learned the risks first-hand. A new USC study published in Science shows many clinicians do not know about patient overdose deaths once they leave their care. Overcoming the disconnect by sharing news of losing a patient makes the opioid crisis more personal and leads doctors to reduce prescriptions.

The American College of Rheumatology (ACR) today expressed its extreme disappointment with a new Centers for Medicare and Medicaid Services (CMS) decision to allow Medicare Advantage (MA) plans to implement step therapy for Part B drugs and cross-manage Part B and D drug utilization.

In many countries, health care reimbursements for drugs are directly related to their value or net health benefits in treating disease. But a new study by researchers at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences , working in collaboration with a group of international clinical and economic experts, shows that's not the case in the U.S.